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ABSTRACT _
Although the healthcare program in Canada is in many
ways universal, there are several differences between the
provinces. Two key federal bodies (the Health Protection
Branch of Health Canada and the Patented Medicine
Prices Review Board) are involved in the drug review
process. In addition, the Canadian Coordinating Office
for Health Technology Assessment (CCOHTA), an orga-
nization funded jointly by provinces and the federal gov-
ernment, reviews new or existing drugs at the request of
provinces. Each province or territory and the federal gov-
ernment has its own drug plan or plans. The 10 Canadian
provinces require a notice of compliance, information on
pricing, and clinical and comparative information for sub-
mission of a new drug. Over the last 3 years, 8 of the 10
provinces have required pharmacoeconomic analyses to
be added to the submissions. Four of the eight provinces
requiring pharmacoeconomic evaluations have specified
that these evaluations should be made according to the
Although the healthcare program in Canada is inmany ways universal, there are several differ-
ences between the provinces. Money from federal
taxes is allocated to healthcare expenditures, which
is then divided among the different provinces of
Canada. The Canada Health Act determines the ba-
sic services covered by all provinces, but interpreta-
tion varies considerably from province to province.
Coverage of drugs is mentioned only once in this
Act, when it states that the provinces shall cover all
drugs for hospitalized patients. This constitutes ap-
proximately 15% of total drug costs. The remaining
85% are outpatient drug costs, less than half of
which are covered by government drug plans. In the
1960's and 1970's many provinces began Pharma-
care programs, which covered more and more drugs.
Recently, however, that coverage has been eroded,
and the patient's share in paying for prescriptions
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Canadian Coordinating Office for Health Technology
Assessment guidelines. A review of the utilization pat-
terns of lipid-lowering therapies is presented in this Cana-
dian context. Statins comprised 80% of the lipid-lowering
drug market in 1995. Prescribers use statins available in
Canada interchangeably for all approved and nonap-
proved indications. The newest starin, atorvastatin, has at-
tained a market share for new prescriptions equivalent to
simvastatin and pravastatin, despite the lack of clinical
outcome studies. CCOHTA reviewed the evidence of effi-
cacy and effectiveness of statins, evaluated whether signifi-
cant differences existed between statins, and analyzed
published economic evaluations. It found that treatment
of higher-risk patients with statins is more cost-effective
than that of lower-risk subjects. The evaluation also con-
cluded that the statins, as a class, probably act in reduc-
ing LDL and raising HDL, resulting in beneficial clinical
outcomes.
and their annual deductibles has increased, primarily
a result of increasing drug costs in the face of general
reductions in government budgets.
Drug expenditures for the treatment and pre-
vention of cardiovascular diseases have been ris-
ing quickly, especially for the newer lipid-lowering
agents, in particular the so-called statin drugs. Car-
diovascular diseases are a leading cause of death in
Canada. In 1992, 22 % of total deaths were due to
ischemic heart diseases, 38% of them occurring on
hospital admissions [1] with rates rising according
to age in men and women up to age 75. In a study
performed on the whole Canadian population be-
tween 1986 and 1990 [2], 46% of hyperlipidemic
patients had total cholesterol values above 5.2
mmol/L (200 mg/dL). Although variations exist ac-
cording to age and sex, these statistics are compa-
rable with those of a number of other countries, in-
cluding the United States. Among men with total
cholesterol above 5.2 mmollL, 36% were hyper-
tensive, 85% were obese (body mass index 2:27),
8% were diabetic, and 61 % smoked one or more
cigarettes per day. Besides having cholesterol levels
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*According to Canadian Coordinating Office for Health Technology Assess-
ment guidelines (see text).
Table I Documentation required by the 10 Canadian
provinces for submission
Submission ofNew Drugs to the Formulary
Documentation required for a drug submission to a
provincial formulary varies from one province to
another (Table 1). The 10 Canadian provinces re-
quire an NOC, information on pricing, and clinical
and comparative information. Over the last 3 years,
8 out of the 10 provinces have required pharrnaco-
economic analyses to be performed and their results
added to the submissions. Four of the eight prov-
inces requiring pharmacoeconomic evaluations have
specified that these evaluations should be made ac-
cording to the CCOHTA guidelines. These guide-
lines were first approved in December 1994. They
were revised in 1997 and the second edition is now
available through the Internet [3]. A majority of
provinces also require a value-for-money appraisal.
Provincial Drug Plan
Each province or territory and the federal govern-
ment has its own drug plan or plans. The federal
government makes its own decisions regarding
coverage for a number of programs including First
Nations, the military, and the Royal Canadian
Mounted Police. The members of each drug plan
committee independently review available studies
and data. Usually, provincial plans cover seniors
over 65, the indigent population, and citizens on
welfare or social allowance, but this coverage var-
ies greatly among the provinces. Some provinces
have special drug programs that cover the cost of
drugs regardless of age or socioeconomic class. For
example, most provincial governments cover AIDS
drugs. However, there are often deductibles that
vary among provincial plans.
In 1996, about $10.8 billion ($Cdn) was spent
on drugs in Canada, representing 14% of health-
care expenditures. Thirty-six percent of that money
came from governments, which means that two-
thirds of every dollar spent on drugs in Canada is
covered by third-party payers or patients.
10 (100)
10 (100)
5 (50)
10(100)
10 (100)
7 (70)
8 (80)*
Number of provinces
requiring document (%)
Notice of compliance
Pricing information
Supply information
Clinical information
Comparative information
Value for money
Pharmacoeconomic analysis
Document
Canadian Drug Approval Process
Key Bodies
Two key federal organizations are involved in the
Canadian drug approval process. The Therapeutic
Products Program is under the Health Protection
Branch (HPB) of Health Canada and is similar to
the FDA in the United States. The HPB examines
randomized controlled trials, determines a prod-
uct's efficacy and safety, and determines approved
indication(s}. Once a drug is approved, a notice of
compliance (NOC) is issued whereupon a company
may market the product.
The Patented Medicine Prices Review Board is
responsible for regulating the maximum prices that
patentees may charge for patented prescription and
nonprescription drugs sold in Canada for human
and veterinary use. The legislation that provides the
Board with its authority sets out which factors
must be taken into account in determining whether
the price of a patented medicine is excessive. These
factors include changes in the Consumer Price In-
dex, the prices of other drugs that treat the same
disease, and the prices of drugs in other countries
(i.e., France, Germany, Italy, Sweden, Switzerland,
the United Kingdom, and the United States).
A third body, the Canadian Coordinating Office
for Health Technology Assessment (CCOHTA), was
created 8 years ago by the federal and provincial
governments to assess various health technologies.
After an independent audit, it was expanded to in-
clude the conducting of clinical and economic com-
patative evaluation of pharmaceuticals. Using exist-
ing information, pharmacoeconomic analyses are
conducted on both new and existing medications.
Pharmaceutical firms, however, are not mandated
by law to have their products undergo clinical and
economic comparative studies.
above 5.2 mmollL, 64% of men had one or more
risk factors, and 22 % had two or more risk fac-
tors. Similar findings were observed for women.
Values tended to rise with age. Some variations in
smoking habits were found between provinces,
with the highest percentage of smokers observed in
Quebec. Interestingly, the highest incidence of car-
diovascular events was also found in that province.
In the current Canadian context, this paper pre-
sents the decision-making process for formulary
additions and deletions, reviews the utilization
patterns of statins, and provides some of the key
findings from an independent evaluation of statins
byCCOHTA.
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Although these are not formal pharmacoeconomic
studies, they provide some information on what
should be expected for the money to be spent.
In four provinces, pharmaceutical companies
are allowed to present information before the drug
receives an NOe. Submissions can be presented or
information provided. The ability to fast-track ap-
proval is allowed in 6 of the 10 provinces. The av-
erage length of time required for review of a partic-
ular product is 3 to 4 months.
Unlike the provinces, third-party payers gener-
ally do not perform detailed evaluation of drugs.
Rather, they tend to follow the province's deci-
sions on drugs with respect to their coverage. The
influence of provinces on private third-party payers'
formularies is thus considerable.
Formulary Control
There is much interchangeability in the formulary
control measures that are applied. Although about
80% of all prescriptions in Canada are for generics,
the amount spent on brand-name drugs exceeds the
amount spent on generic products. Provinces may
also impose restrictions on the availability of some
drugs. These restrictions vary from province to prov-
ince even for the same drug. Restrictions include im-
posing strict criteria of use (e.g., growth hormone),
limiting the number of prescribing clinicians (e.g.,
AIDS drugs), and selecting dispensing centers (e.g.,
cyclosporine). In the province of Ontario, compli-
ance with treatment is required for some patients to
be covered for that treatment. This applies primarily
to expensive drugs for relatively rare conditions. For
example, if patients with multiple sclerosis fail to
comply with their treatment protocol when using in-
terferon beta-1b (Betaseron, Berlix Canada, Lachine,
Quebec), the drug will not be covered.
Formulary control measures also include drug
utilization reviews, performed by most of the prov-
inces. Many of the studies performed by CCOHTA
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evaluate not only new drugs but also older ones.
Variations in utilization patterns may also be ex-
amined. For example, a soon-to-be-released study
on drug therapies for the treatment of attention
deficitlhyperactivity disorder includes some analy-
sis of methylphenidate use over time in one of the
provinces.
General Review Process
Following a submission by a manufacturer, the
provinces apply a general review process. First, the
experts review and provide comments to an advi-
sory committee within each province. Second, the
advisory committee makes its own recommenda-
tions to the Ministry of Health. If a pharmaceutical
company wishes to have these recommendations re-
reviewed, the appeal process is usually informal.
The provinces do not always make similar deci-
sions. For example, the above-mentioned Betaseron
was initially included on the formulary of only three
provinces. The other provinces delayed their deci-
sion pending further information. Since the initial
decision, patient advocacy groups have altered the
policy in several provinces.
Utilization Patterns of Statins in Canada
Canadian Guidelines
The Canadian Guidelines for the Detection and
Management of Hypercholesterolemia [4] give in-
dications as to when a treatment with a lipid-lower-
ing agent should occur. Risk factors such as presence
of coronary heart disease (CHD), age, diabetes, fam-
ily history, hypertension, and high density lipopro-
tein (HDL) levels less than 0.9 rnmol/L (35 mg/dl.)
or the low density lipoprotein (LDL)/HDL ratio
greater than five are considered. Treatment goals
for men 40-70 years old and women 50-70 years
old are recommended, categorized according to
number of risk factors (Table 2). A subject suffer-
Table 2 Treatment goals for men 40-70 years old and women 50-70 years old according to the Canadian guidelines for the
management of hypercholesterolemia
Criteria for drug therapy Treatment goals
Number of Ten-year risk LDL TG LDL TG
risk factors ofCHD (mmol/L) TClHDL (mmol/L) (mmoI/L) TC/HDL (mmoI/L)
2:4 or presence of CHD Very high (2:40%) >3.5 >5 >3 2.5 4 2
3 High (20-39%) >4.5 >6 >3 3.5 5 2
2 Moderate (10-19%) >5 >7 >3 4.0 6 2
osl Low «10%) >6 >8 >4 5.0 7 3
Data from [4].
CHD, coronary heart disease; HDL, high density lipoproteins; LDL, low density lipoproteins; TC, total cholesterol; TG, triglycerides.
All cholesterol measures in mmollL Conversion to mgldL is accomplished by dividing the mmollL figure by 0.02586 (JAMA Website. Systeme International (51) Con-
version Factors for Selected Laboratory Components, http://www.ama-assn.orglpublidjournalsljamal7l005tl.htm).
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Table 3 Prescription of statins in Canada according to diagnosis*
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Diagnosis Lovastatin (%) Simvastatin (%) Fluvastatin (%) Pravastatin (%) Total (%)
Hyperlipidemia (other + unspecified) 41 49 50 55 47
Pure hypercholesterolemia 41 43 40 33 40
Chronic IHD without hypertension 8 I 2 1 4
Coronary arterosclerosis without hypertension 4 3 2 I 3
Essential hypertension 2 2 5 2
Other 4 2 6 5 4
*Unpublished data from Intercontinental Medical Statistics (IMS) Canada, Toronto, Ontario.
IHO, ischemic heart disease.
ing from CHD or with four or more risk factors
has a 10-year risk of cardiovascular disease greater
than or equal to 40%. Additional criteria for drug
therapy include LDL cholesterol and triglyceride
levels and the ratio of total cholesterol to LDL cho-
lesterol. More aggressive management is recom-
mended as risk factors increase.
Availability and Prescription ofStatins in Canada
Five statins are available in Canada. Lovastatin was
the first statin made available in Canada at 20-80
mg daily. Other available statins include fluvastatin
at 20-40 mg daily at bedtime or 40 mg twice daily,
pravastatin at 10-40 mg daily, and simvastatin at
5-40 mg daily. Atorvastatin was released last year
and is available at 10-80 mg daily. [Note: Since this
conference, a sixth statin, cerivastatin (Baycol, Bayer
Inc., Etobicoke, Ontario), has been granted an NOC
from the HPB.]
Statins are prescribed preferentially to other lipid-
lowering agents (including bile-acid sequestrants, fi-
brates, and niacin derivatives). They have risen from
60% of the market share in 1991 to 80% in 1995.
The utilization of simvastatin and pravastatin in-
creased dramatically in late 1996 (Intercontinental
Medical Statistics [IMS] Canada, Toronto, Ontario,
unpublished data), after the release of statin studies
that showed that cardiovascular events are signifi-
cantly reduced in high-risk patients [5,6]. Simvas-
tatin and pravastatin each have captured approxi-
mately 30% of the marke~'Jwhile lovastatin and
fluvastatin have 17% and 8% of the market, respec-
tively. Atorvastatin, a statin with little outcomes
data, was released in April 1997. Bythe end of 1997,
new prescriptions for atorvastatin were almost equal
to new prescriptions for simvastatin and pravastatin,
possibly due to its greater ability to reduce LDL.
Similar trends have been demonstrated in the United
States (IMS Canada, Toronto, Ontario, unpublished
data). There is little regional variation in the per-
centage of statin prescriptions versus other lipid-
lowering agents. General practitioners represent
two-thirds of statin prescribers (64.9%), followed by
family physicians (16.2%). Cardiologists make up
only 8.1% of statin prescribers. Similar percentages
are observed for prescribers of all lipid-lowering
agents.
Approved indications provided by the HPB state
that statins can be used for the treatment of type 2a
and 2b hypercholesterolemia and for CHD. Pharma-
ceutical companies can market their products only
according to the HPB indications that appear in the
official monographs of the drugs. A cautionary note
is provided for lovastatin that relates to its unproven
value for CHD. For pravastatin, there is mention
that coronary events are decreased by a treatment
with this drug, but that the overall mortality is not
affected. A caution is given also for simvastatin with
respect to the extrapolation of the observed decrease
in overall mortality to subpopulations of women,
subjects with angina, and subjects without CHD.
The prescribing patterns according to diagnosis
are fairly similar for each of the statins (Table 3).
Prescriptions for hyperlipidemia account for 41-
55% of all diagnoses; and the figures vary between
33% and 43% for pure hypercholesterolemia. There
is much interchangeability among physicians, at
least in terms of which statins are prescribed for
which condition. A significant percentage of statins
is used in primary prevention for patients with hy-
percholesterolemia without CHD (Table 4). Patients
aged 40 to 59 years old account for 40% of statin
prescriptions, followed by subjects aged 65 and
older with 33% of prescriptions for all diagnoses.
Table 4 Prescription of statins in Canada according to
diagnosis and age*
Pure All other All diagnoses
Age range hypercholesterolemia diagnoses (%) combined (%)
20-39 8 3 5
40-59 44 41 40
60-64 16 16 15
65+ 29 39 33
Unspecified 2 2 7
*Unpublished data from Intercontinental Medical Statistics (IMS)Canada. Tor-
onto, Ontario.
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Examination of prescribing habits indicates that,
with the exception of simvastatin (which is less fre-
quently prescribed by general practitioners and fam-
ily physicians), the different statins are prescribed in
similar percentages by different categories of pre-
scribers. They are also prescribed for all age groups.
All statins, with a few exceptions, are prescribed for
various indications.
CCOHTA's Evaluation ofStatins
Concerned by the increasing use of statins, the Ca-
nadian provinces commissioned CCOHTA to ex-
amine how statins should be used, whether they
are being used appropriately, and for what popula-
tions. We evaluated clinical trials and about 30
pharmacoeconomic studies on statins found in the
literature. We subsequently used Canadian data to
evaluate pharmacoeconomic studies in the Cana-
dian context. Our objectives were to review efficacy
of statins, to determine if differences exist between
drugs, to assess which populations would most ben-
efit from treatment, and to review cost and cost-
effectiveness of these lipid-lowering agents. Results
of this analysis indicated that the most cost-effective
use of statins can be obtained by using them in the
following population subgroups: 1) in secondary
prevention for adults (35-70 years old) with high
LDL levels; 2) in secondary prevention for adults
(35-70 years old) with mild to moderately high
LDL levels; and 3) in primary prevention for adult
men (35-65 years old) with high LDL levels and
multiple CHD risk factors.
There is now clinical evidence of significant ben-
eficial effects with three of the statins: pravastatin,
simvastatin, and lovastatin. These include reduc-
tions in: 1) nonfatal MI and death from all cardio-
vascular causes, using pravastatin as primary pre-
vention of coronary heart disease in men with high
cholesterol but no previous history of cardiovascu-
lar disease [5]; 2) nonfatal MI, coronary deaths, and
death, using simvastatin in the secondary preven-
tion of cardiovascular disease [6]; 3) fatal CHD and
nonfatal MI combined, nonfatal MI, and strokes,
using pravastatin as secondary prevention in pa-
tients with relatively normal cholesterol [7]; and 4)
first acute major coronary events, MI, and unstable
angina, using lovastatin as preventive therapy in
patients with average cholesterol [8]. The review of
statins also concluded that all statins would likely
produce clinical benefits. The conclusion was de-
rived from the strong epidemiological evidence of
the relationship between cholesterol levels (particu-
larly HDL and LDL) and cardiac events, the simi-
larity in the mechanism of action of statins in re-
Otten
ducing cholesterol, the lack of significant differences
in their adverse effects profile, and the consistent
benefits seen in clinical studies despite varying
populations. Because the statins differ primarily in
their impact on LDL rather than HDL, cost-effec-
tiveness could be based on their ability to reduce
LDL. Hence, in Canada, simvastatin would be more
cost-effective for 21-29% LDL reduction at 5 mg
and for 30-35% LDL reduction at 10 mg. For an
LDL reduction of 36-39% and greater than 40%,
atorvastatin would be the more cost-effective prod-
uct at 10 and 20 mg, respectively.
Conclusions
An extensive drug review process is used in Can-
ada, beginning with the request to market a prod-
uct to listing a drug on a formulary. Each province
in Canada has developed a strict formulary system.
Increasing drug expenditures and decreased gov-
ernment budgets have forced provinces to more
critically evaluate requests for additions to the for-
mularies, as well as to evaluate current formulary
items. Statin drug use has increased substantially in
Canada. A critical evaluation of their benefits and
cost-effectiveness has determined that they are
cost-effective in high-risk patients for both the pri-
mary and secondary prevention of cardiovascular
disease. There still remain a number of unanswered
questions. These include: How useful and cost-
effective are statins in the elderly? Should the goal
of therapy be to attain a particular LDL level or a
maximum percentage reduction in LDL? Should
target cholesterol levels be altered based on recent
studies? Are other proposed mechanisms of action
of statins important in determining clinical benefit?
Finally, although these drugs provide a clear bene-
fit at a reasonable cost in selected populations,
poor patient compliance may negate projected
beneficial outcomes.
This article was prepared with the assistance of BioMed-
Com Consultants inc., Montreal, Canada.
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